Susquehanna International Group, LLP Day One Biopharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$12.72 - $16.03 $35,616 - $44,884	-2,800 Reduced 12.73%	19,200 $267,000
Q2 2024 Aug 15, 2024	BUY	$12.03 - $17.69 $264,660 - $389,180	22,000 New	22,000 $303,000
Q2 2023 Aug 11, 2023	SELL	$11.74 - $14.47 $38,742 - $47,751	-3,300 Reduced 16.34%	16,900 $201,000
Q1 2023 May 16, 2023	SELL	$12.75 - $23.41 $561,000 - $1.03 Million	-44,000 Reduced 68.54%	20,200 $270,000
Q4 2022 Feb 14, 2023	SELL	$18.77 - $22.0 $140,775 - $165,000	-7,500 Reduced 10.46%	64,200 $1.38 Million
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $290,988 - $470,289	17,700 Added 32.78%	71,700 $1.44 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $17.9 $308,880 - $966,599	54,000 New	54,000 $967,000

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $945M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.